Raison et al. conducted a randomized controlled trial of the tumor necrosis factor (TNF) antagonist infliximab in patients with treatment-resistant depression, demonstrating that those with elevated inflammatory markers had a better response to treatment [120]. This evidence concerns the gene TNF and depressive disorder.